Jacobs Levy Equity Management
ZVRA icon

Jacobs Levy Equity Management’s Zevra Therapeutics ZVRA Stock Holding History

Jacobs Levy Equity Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-91,118
Closed -$446K – 1064
2024
Q2 		$446K Buy
91,118
+56,411
+163% +$267K ﹤0.01% 851
2024
Q1 		$201K Buy
34,707
+17,557
+102% +$108K ﹤0.01% 891
2023
Q4 		$112K Sell
17,150
-45,425
-73% -$212K ﹤0.01% 949
2023
Q3 		$302K Buy
+62,575
New +$312K ﹤0.01% 875
2019
Q2 		– Sell
-8,258
Closed -$221K – 1042
2019
Q1 		$221K Buy
8,258
+4,536
+122% +$167K ﹤0.01% 880
2018
Q4 		$106K Buy
3,722
+1,363
+58% +$55.2K ﹤0.01% 939
2018
Q3 		$181K Sell
2,359
-725
-24% -$56.6K ﹤0.01% 936
2018
Q2 		$321K Buy
3,084
+319
+12% +$31.1K 0.01% 877
2018
Q1 		$350K Sell
2,765
-609
-18% -$58.9K 0.01% 838
2017
Q4 		$219K Sell
3,374
-75
-2% -$4.52K ﹤0.01% 890
2017
Q3 		$204K Buy
+3,449
New +$184K ﹤0.01% 858

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's ZVRA Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 91,118 shares — an estimated $446K sold.

Jacobs Levy Equity Management first reported a position in ZVRA in Q3 2017 and held it in 11 quarters. The position peaked at $446K in Q2 2024. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 91,118 Zevra Therapeutics shares in Q3 2024, an estimated $446K.
  • Jacobs Levy Equity Management first reported a position in Zevra Therapeutics in Q3 2017 and held it in 11 quarters.
  • Jacobs Levy Equity Management's Zevra Therapeutics position peaked at $446K in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.